Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.

Abstract: The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease.

Abstract: A method of treating an ocular disease in a subject includes delivering a pharmaceutical composition into a ciliary muscle of the subject and inducing transfection of the therapeutic nucleic acid into the ciliary muscle by exposing the pharmaceutical composition to ultrasound. The pharmaceutical composition comprises echo-contrast agent microbubbles and a therapeutic nucleic acid.

Abstract: Treatment of a disease associated with retinal degenerative disorder. The present invention relates to human Transferrin or an active fragment thereof for use in the treatment of a disease associated with retinal degenerative disorder.

Abstract: The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing.

Abstract: The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.

Abstract: A method for intracellular delivery of isolated naked nucleic acids into a biological tissue or organ, that includes (a) contacting the tissue or organ with an efficient amount of at least one active corticosteroid, and (b) contacting the tissue or organ treated in step b with an efficient amount of isolated naked nucleic acids, wherein step (a) is carried out for a period of time ranging from at least five minutes to at most two hours and being immediately followed by step (b).

Abstract: The present invention relates to the use of blockers of ion channels regulated by the SUR subunit, for the treatment and/or prevention of eye diseases associated with ischemia and/or retinal excitotoxicity.

Abstract: The present invention relates, generally, to improved methods of delivering a biologically active agent, in particular a therapeutic or prophylactic nucleic acid, to the ocular sphere of a subject comprising administering said agent to the ciliary body tissue(s) or cells and/or to the extra-ocular muscle tissue or cells. More particularly, the invention relates to devices, their uses, notably in gene therapy, and to methods for treating pathologies of the ocular sphere by specific ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration of a therapeutic product and transfer thereof into the ocular tissue to be treated. This invention also relates to pharmaceutical compositions comprising the product in a form suitable for ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration, their preparation and uses.

Abstract: An injection device for injecting a product into an eye, said device comprising an injection needle and a support on which the injection needle is fixed, said device being characterized in that it comprises a locating mark disposed in such a way that the latter can be placed in contact with a defined bearing region of the surface of the eye, before any contact of the injection needle with said surface, and can then be kept in contact with said bearing region during a stage of penetration of said injection needle through said surface of the eye.

Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.

Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.

Abstract: The present invention provides a device and a method for the enhanced retinal delivery of nucleic acid therapeutics utilizing iontophoresis to evoke a transient elongation of the Müller Cells of a mammalian eye. The enhanced retinal deposition can be achieved by either a topical application, subconjunctival, or an intravitreal injection of the nucleic acid composition followed by, preceded by, or administered simultaneously with the iontophoretic application. The present invention thus provides a particularly advantageous method for the treatment of ocular diseases comprising the in vivo administration of a nucleic acid capable of alleviating the symptoms of a disease, the delivery of the nucleic acid being enhanced by using iontophoresis. This method can be applied particularly to the diseases of the retina resulting from an alteration of a gene expression and/or the over-expression of particular growth factors.

Abstract: The present invention relates, generally, to improved methods of delivering a biologically active agent, in particular a therapeutic or prophylactic nucleic acid, to the ocular sphere of a subject comprising administering said agent to the ciliary body tissue(s) or cells and/or to the extra-ocular muscle tissue or cells. More particularly, the invention relates to devices, their uses, notably in gene therapy, and to methods for treating pathologies of the ocular sphere by specific ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration of a therapeutic product and transfer thereof into the ocular tissue to be treated. This invention also relates to pharmaceutical compositions comprising the product in a form suitable for ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration, their preparation and uses.

Abstract: A method for treating eye diseases by injecting intraocularly or periocularly a composition comprising an emulsion and optionally at least a pharmaceutical active ingredient.

Abstract: The present invention provides a method for enhancing the in vivo delivery of chimeric oligonucleotides, containing for example DNA/2′OMeRNA, into cells of a plant, an animal or a human, comprising a step of applying topically to or injecting into a tissue, or tissue adjacent to a tissue, containing said cells, a composition comprising said chimeric oligonucleotide, followed by, preceded by, or simultaneously to a step of transferring said chimeric oligonucleotide into said cells by iontophoresis, and relates to a gene therapy method comprising the iontophorically transfer of a chimeric oligonucleotide DNA/2′OMeRNA. The present invention is also directed to particular chimeric oligonucleotides DNA/2′OMeRNA capable of inducing or inhibiting the expression of a specific gene involved in eye function by inducing or reverting a mutation in that specific gene, and their use as therapeutic composition for preventing or treating ocular diseases.